BioCatalystWatch
IPHAWorkspace / IPHA / OverviewCompany library
Price
Market cap
Next catalystExpected 2026Monalizumab · Data readoutSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

IPH4502

Nectin-4

PreINDP2P3FilingApproved
Upcoming / outlook

KIR3DL2

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

KIR3DL2

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

KIR3DL2

PreINDP1P2P3FilingApproved
Upcoming / outlook

IPH4502

Nectin-4

PreINDP2P3FilingApproved
Upcoming / outlook

KIR3DL2

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

Other pipelines

IPH4502

Nectin-4

PreINDP1P2P3FilingApproved
Upcoming / outlook

Lacutamab (IPH4102)

KIR3DL2

PreINDP1P2P3FilingApproved
IPH6101/SAR’579

Multispecific antibody

CD123 × NKp46 × CD16a

PreINDP1P2P3FilingApproved
IPH6101/SAR’579

Multispecific antibody

CD123 × NKp46 × CD16a

PreINDP1P2P3FilingApproved
IPH6101/SAR’579

Multispecific antibody

CD123 × NKp46 × CD16a

PreINDP1P2P3FilingApproved
Lirilumab

KIR2DL1/2/3

PreINDP1P2P3FilingApproved
Lirilumab

KIR2DL1/2/3

PreINDP1P2P3FilingApproved
IPH65

CD20

Partner / License out

CD39

PreINDP1P2P3FilingApproved
Monalizumab

NKG2A

PreINDP1P2P3FilingApproved
Monalizumab

NKG2A

PreINDP1P2P3FilingApproved
Upcoming / outlook

Multispecific antibody

B7-H3 × NKp46 × CD16

History / paused

Monalizumab

NKG2A

PreINDP1P2P3FilingApproved

CD20 × NKp46 × CD16a × CD122 (IL-2Rβ)

PreINDP1P2P3FilingApproved

C5aR1 (CD88)

PreINDP1P2P3FilingApproved

C5aR1 (CD88)

PreINDP1P2P3FilingApproved

C5aR1 (CD88)

PreINDP1P2P3FilingApproved

Multispecific antibody

BCMA × NKp46 × CD16

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Source and basis

Source and basis

Source and basis

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

IPHA PR & News

PR & News

IPHA SEC archive